IRIS
CONSOLARO, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 15.757
AS - Asia 1.673
NA - Nord America 762
SA - Sud America 133
AF - Africa 41
OC - Oceania 1
Totale 18.367
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 15.465
SG - Singapore 793
US - Stati Uniti d'America 725
CN - Cina 417
VN - Vietnam 264
FR - Francia 131
BR - Brasile 76
HK - Hong Kong 58
DE - Germania 31
GB - Regno Unito 24
AR - Argentina 23
IN - India 21
FI - Finlandia 19
JP - Giappone 18
MX - Messico 15
IQ - Iraq 14
CA - Canada 13
NL - Olanda 13
BD - Bangladesh 12
ID - Indonesia 12
EC - Ecuador 10
RU - Federazione Russa 10
TR - Turchia 9
MA - Marocco 8
SE - Svezia 8
CH - Svizzera 7
CO - Colombia 7
ES - Italia 7
IE - Irlanda 7
KE - Kenya 7
PK - Pakistan 7
VE - Venezuela 7
ZA - Sudafrica 7
PH - Filippine 6
DZ - Algeria 5
EG - Egitto 5
SA - Arabia Saudita 5
TN - Tunisia 5
AT - Austria 4
PL - Polonia 4
PY - Paraguay 4
TH - Thailandia 4
UA - Ucraina 4
BO - Bolivia 3
CL - Cile 3
DO - Repubblica Dominicana 3
JO - Giordania 3
LB - Libano 3
RO - Romania 3
RS - Serbia 3
AL - Albania 2
AM - Armenia 2
AZ - Azerbaigian 2
BE - Belgio 2
BY - Bielorussia 2
CZ - Repubblica Ceca 2
KZ - Kazakistan 2
MY - Malesia 2
NP - Nepal 2
OM - Oman 2
PT - Portogallo 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
UZ - Uzbekistan 2
AE - Emirati Arabi Uniti 1
AF - Afghanistan, Repubblica islamica di 1
AO - Angola 1
AU - Australia 1
CR - Costa Rica 1
CY - Cipro 1
GE - Georgia 1
GR - Grecia 1
HU - Ungheria 1
IR - Iran 1
JM - Giamaica 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
LT - Lituania 1
LU - Lussemburgo 1
MD - Moldavia 1
MM - Myanmar 1
MN - Mongolia 1
NO - Norvegia 1
PA - Panama 1
PR - Porto Rico 1
SI - Slovenia 1
SN - Senegal 1
TG - Togo 1
TZ - Tanzania 1
Totale 18.367
Salva come PNG Salva come JPEG
Città #
Genova 8.887
Genoa 3.801
Rapallo 1.366
Vado Ligure 1.299
Singapore 381
San Jose 232
Council Bluffs 129
Lauterbourg 115
Ashburn 91
Ho Chi Minh City 80
Beijing 71
Hanoi 65
Hong Kong 56
New York 42
Bordighera 31
Frankfurt am Main 25
Santa Clara 21
Tokyo 17
Haiphong 16
Orem 14
Chicago 11
Da Nang 11
Helsinki 10
Los Angeles 10
Mexico City 9
Amsterdam 8
Chennai 8
Lappeenranta 8
Milan 8
Buffalo 7
Cardiff 7
Shanghai 7
City of London 6
Tianjin 6
Biên Hòa 5
Denver 5
Dublin 5
Hải Dương 5
Montreal 5
Paris 5
Zurich 5
Alessandria 4
Baghdad 4
Kyiv 4
La Spezia 4
Nairobi 4
Palermo 4
Rio de Janeiro 4
Rome 4
Toronto 4
Warsaw 4
Agadir 3
Amman 3
Belgrade 3
Cairo 3
Cape Town 3
Caracas 3
Des Moines 3
Erbil 3
Esmeraldas 3
Guangzhou 3
Guayaquil 3
Islamabad 3
Manaus 3
Manchester 3
Nuremberg 3
Porto Alegre 3
Stockholm 3
São Paulo 3
Thái Bình 3
Tunis 3
Acalanes Ridge 2
Adana 2
Atlanta 2
Avellaneda 2
Barcelona 2
Benito Juarez 2
Bogotá 2
Brasília 2
Bắc Giang 2
Campinas 2
Can Tho 2
Ciudad del Este 2
Dallas 2
Dammam 2
Gothenburg 2
Hưng Yên 2
Istanbul 2
Jeddah 2
Johannesburg 2
Kensington 2
Lahore 2
Lausanne 2
Lisbon 2
London 2
Maceió 2
Machala 2
Madrid 2
Marrakesh 2
Marseille 2
Totale 17.048
Salva come PNG Salva come JPEG
Nome #
Juvenile Idiopathic Arthritis: Diagnosis and Treatment 214
A Meta-Analysis to Estimate the Placebo Effect in Randomized Controlled Trials in Juvenile Idiopathic Arthritis 212
Remission, minimal disease activity, and acceptable symptom state in juvenile idiopathic arthritis: Defining criteria based on the juvenile arthritis disease activity score 199
MRI versus conventional measures of disease activity and structural damage in evaluating treatment efficacy in juvenile idiopathic arthritis. 198
Parent and child acceptable symptom state in juvenile idiopathic arthritis. 195
Cross-cultural adaptation and psychometric evaluation of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) in 54 languages across 52 countries: review of the general methodology 187
Development and initial validation of a composite disease activity score for systemic juvenile idiopathic arthritis 185
The Italian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 181
Whole-body MRI in the assessment of disease activity in juvenile dermatomyositis 181
Intra-articular corticosteroids versus intra-articular corticosteroids plus methotrexate in oligoarticular juvenile idiopathic arthritis: a multicentre, prospective, randomised, open-label trial 178
The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 178
The Slovak version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 178
IL-1 Inhibition in Systemic Juvenile Idiopathic Arthritis 177
The Croatian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 175
A New Approach to Clinical Care of Juvenile Idiopathic Arthritis: The Juvenile Arthritis Multidimensional Assessment Report 172
Advances in biomarkers for paediatric rheumatic diseases 171
Clinical outcome measures in juvenile idiopathic arthritis 170
Disease status, reasons for discontinuation and adverse events in 1038 Italian children with juvenile idiopathic arthritis treated with etanercept 170
Current Research in Outcome Measures for Pediatric Rheumatic and Autoinflammatory Diseases 168
Development and validation of a composite disease activity score for juvenile idiopathic arthritis 163
Outcome and predicting factors of single and multiple intra-articular corticosteroid injections in children with juvenile idiopathic arthritis 162
Development and testing of a hybrid measure of muscle strength in juvenile dermatomyositis for use in routine care 162
Evaluation of 21-Numbered Circle and 10-Centimeter Horizontal Line Visual Analog Scales for Physician and Parent Subjective Ratings in Juvenile Idiopathic Arthritis 161
Development and validation of a composite disease activity score for measurement of muscle and skin involvement in juvenile dermatomyositis 161
A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis 160
Development and initial validation of composite parent and child centered disease assessment indices for juvenile idiopathic arthritis. 159
Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016 157
Seeking insights into the EPidemiology, treatment and Outcome of Childhood Arthritis through a multinational collaborative effort: Introduction of the EPOCA study. 155
Disease activity and damage in juvenile idiopathic arthritis: Methotrexate era versus biologic era 155
A child with a novel ACAN missense variant mimicking a septic arthritis 155
An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis 154
Recent therapeutic advances in juvenile idiopathic arthritis 153
Pharmacovigilance in juvenile idiopathic arthritis patients treated with biologic or synthetic drugs: combined data of more than 15,000 patients from Pharmachild and national registries 151
Factors associated with achievement of inactive disease in children with juvenile idiopathic arthritis treated with etanercept. 150
Filling the Gap: Toward a Disease Activity Tool for Systemic Juvenile Idiopathic Arthritis 150
Phenotypic variability and disparities in treatment and outcomes of childhood arthritis throughout the world: an observational cohort study 150
The Turkish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 148
Development and testing of reduced joint counts in juvenile idiopathic arthritis. 147
Defining criteria for disease activity States in nonsystemic juvenile idiopathic arthritis based on a three-variable juvenile arthritis disease activity score. 147
The Algerian Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 147
The Bulgarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 146
The Chilean Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 145
The Colombian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 144
The Swedish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 143
Performance of current guidelines for diagnosis of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. 142
Predictors of effectiveness of anakinra in systemic juvenile idiopathic arthritis 142
TCR repertoire sequencing identifies synovial Treg cell clonotypes in the bloodstream during active inflammation in human arthritis 141
The British English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 141
The Flemish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 141
The Finnish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 140
The Russian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 138
The Afrikaans version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 138
The Serbian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 137
The Canadian English and French versions of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 137
The Hindi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 137
Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop 137
The Mexican Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 136
Unraveling the phenotypic variability of juvenile idiopathic arthritis across races or geographic areas - Key to understanding etiology and genetic factors? 135
The Ecuadorian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 135
The Ukrainian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 134
The Castilian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 134
The Lithuanian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 133
The Dutch version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 133
Delineating the role of multiple intraarticular corticosteroid injections in the management of juvenile idiopathic arthritis in the biologic era. 132
The Farsi version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
The Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
The Latvian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
The Swiss French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
The Thai version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 132
Female sex and oligoarthritis category are not risk factors for uveitis in Italian children with juvenile idiopathic arthritis. 131
It is worth including assessment of disease activity state in juvenile arthritis clinical trials. 131
Prevalence of overweight and obesity in 2- to 6-year-old Italian children 131
The Danish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 131
The Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 131
Defining criteria for high disease activity in juvenile idiopathic arthritis based on the juvenile arthritis disease activity score. 131
The Hebrew version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 130
The Czech version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 130
The Estonian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 130
The Georgian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 129
Glucocorticoids in juvenile idiopathic arthritis. 128
The Paraguayan Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 128
The Argentinian Spanish version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 127
Measures of disease activity and damage in pediatric systemic lupus erythematosus: British Isles Lupus Assessment Group (BILAG), European Consensus Lupus Activity Measurement (ECLAM), Systemic Lupus Activity Measure (SLAM), Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), Physician's Global Assessment of Disease Activity (MD Global), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SLICC/ACR DI; SDI). 126
Paediatric rheumatology: Juvenile idiopathic arthritis--are biologic agents effective for pain? 126
Defining criteria for disease activity states in juvenile idiopathic arthritis 126
The Brazilian Portuguese version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 125
The Omani Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 124
The American English version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 123
Determinants of discordance between criteria for inactive disease and low disease activity in juvenile idiopathic arhritis 123
Ghrelin, insulin sensitivity and postprandial glucose disposal in overweight and obese children 122
Critical role of STIR MRI in early detection of post-streptococcal periostitis with dysproteinaemia (Goldbloom's syndrome) 122
The French version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
The Norwegian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 122
The Libyan Arabic version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 121
Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. 120
The Hungarian version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 119
Information technology in paediatric rheumatology 117
The Greek version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR) 117
Analysis of arthritis flares after achievement of inactive disease with methotrexate monotherapy in juvenile idiopathic arthritis 117
Comparison of clinical features and drug therapies among European and Latin American patients with juvenile dermatomyositis. 115
Totale 14.592
Salva come PNG Salva come JPEG
Categoria #
all - tutte 62.767
article - articoli 62.767
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 125.534
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021454 0 0 0 0 0 0 0 0 0 178 70 206
2021/20221.488 72 59 122 119 55 123 61 326 125 175 63 188
2022/20231.632 147 147 21 144 251 274 9 159 276 14 165 25
2023/2024822 35 113 35 110 71 73 89 46 41 35 48 126
2024/20252.973 78 217 111 208 422 365 297 469 75 139 240 352
2025/20264.134 577 161 216 233 667 468 720 217 392 483 0 0
Totale 18.918